Description

Pradaxa (dabigatran etexilate) capsules 150 mg. №60

Ingredients:

Each capsule contains 150 mg of dabigatran etexilate.

Dosage:

The recommended dose is one 150 mg capsule taken orally twice daily.

Indications:

Pradaxa is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

Contraindications:

Do not use Pradaxa in patients with artificial heart valves or those with a history of hypersensitivity to dabigatran.

Directions:

Swallow the capsule whole with a full glass of water. Do not crush or chew the capsule.

Scientific Evidence:

Dabigatran etexilate, the active ingredient in Pradaxa, is a direct thrombin inhibitor that has shown non-inferiority to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. The RE-LY trial demonstrated that dabigatran was as effective as warfarin in reducing the risk of stroke and had a lower risk of intracranial bleeding.

Additional Information:

It is important to note that Pradaxa does not require routine monitoring of coagulation levels like warfarin does, making it a more convenient option for patients. However, patients should be aware of the increased risk of gastrointestinal bleeding associated with Pradaxa use.

Pradaxa has been extensively studied in various clinical trials, consistently showing its efficacy and safety profile. Patients should always consult their healthcare provider before starting Pradaxa to ensure it is the right choice for their medical condition.